Loading quotes...
Forecast
The analysts' average price target is €41.45 (+3,634.23%). The median is €4.46 (+301.80%).
| Buy |
4 |
| Hold |
3 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 7.16m | 25.33% |
| Gross profit | 3.78m | 28.14% |
| Net profit | -6.5m | 11.80% |
| EBITDA | -4.49m | 21.75% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €13.12m |
Number of shares | 11.78m |
52-week high/low | €1.99 - €0.89 |
| Dividends | No |
Beta | 1.66 |
P/E ratio | -0.34 |
PEG ratio | 0.00 |
P/B ratio | 0.46 |
P/S ratio | 0.49 |
Company profile
| Name | Bionano Genomics |
| CEO | Albert A. Luderer |
| Headquarters | San Diego,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 96 |
